It is an often quoted fact that only a small percentage of people with cancer participate in clinical trials, despite there being a large number of studies spanning both types of cancer and therapeutic options that are seeking patients. Acurian has recently talked with a number of pharmaceutical executives and investigative sites to try to better understand the barriers to study participation.

Despite efforts by sites, pharmaceutical companies, the government, and cancer advocacy groups, trial awareness continues to be a major impediment. Many potential trial participants are treated by oncologists who are not investigators. Our research, and that of others, indicates that it is critical that the treating doctor has an awareness of trials nearby for which his/her patients might be eligible. There is an understandable reluctance to initiate discussion about trial participation unless the doctor has the needed information to counsel the patient appropriately. Clearly, it would be beneficial to lower this barrier by providing individual oncologists with relevant information about trials in their areas.

Additionally, patient awareness about trial opportunities could also be heightened. Despite the existence of internet-based trial listings, and similar services from advocacy groups, we at Acurian believe that many potential trial participants are not aware of studies in their area for which they may be eligible. In other therapeutic areas (e.g. asthma, diabetes) recruitment has been done successfully using traditional media (radio, TV, print) to increase awareness, and Acurian has had success using its direct mail to target individuals in its 50+ million database, but these approaches are much less appropriate in oncology.

The challenge remains one of heightening awareness of both the person with cancer and the treating physician. By making both aware of the trial opportunities, it is possible for them to have the necessary discussion on the risks, benefits, and potential appropriateness of trials in oncology. We must continue to work toward giving easily accessible information to the stakeholders so that awareness increases. It will result in greater trial participation.